Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KC1036 in adolescents with advanced Ewing sarcoma
NCT06564272Phase 2Recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of connitinib in Ewing sarcoma, sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoint: Adverse events (AEs). Started Sep 2024; status: recruiting.
02
Drugs
connitinib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT06564272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564272.